CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study

Guideline2014 Jun 24;129(25 Suppl 2):S49-73.

JOURNAL:Circulation. Article Link

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Goff DC Jr, Lloyd-Jones DM, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Keywords: AHA Scientific Statements; biomarkers; cardiovascular disease; cholesterol; primary prevention; risk assessment; risk reduction behavior

Full Text PDF